Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 18;14(6):2077.
doi: 10.3390/jcm14062077.

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Francesca Barei  1 , Paolo Calzari  2 , Elena Pezzolo  3 , Maddalena Napolitano  4 , Mariateresa Rossi  5 , Mario Bruno Guanti  6 , Francesca Caroppo  7   8 , Anna Belloni Fortina  8 , Cataldo Patruno  9 , Anna Campanati  10 , Tommaso Bianchelli  11 , Giovanni Marco D'Agostino  11 , Eustachio Nettis  12 , Francesco Pugliese  12 , Francesca di Vico  4 , Ilaria Trave  13 , Emanuele Cozzani  13 , Luca Stingeni  14 , Katharina Hansel  14 , Matilde Dall'Olio  15 , Laura Grigolato  5 , Rosa Coppola  16 , Vincenzo Panasiti  16   17 , Martina Maurelli  18 , Giampiero Girolomoni  18 , Michela Ortoncelli  19 , Simone Ribero  19 , Angelo Valerio Marzano  1   2 , Silvia Mariel Ferrucci  1
Affiliations

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Francesca Barei et al. J Clin Med. .

Abstract

Background/Objectives: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. Methods: A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients. EASI (Eczema Area and Severity Index), P-NRS (Pruritus Numerical Rating Scale), DLQI (Dermatology Life Quality Index), and ADCT (Atopic Dermatitis Control Tool) were recorded up to 52 weeks of treatment. Results: The EASI, P-NRS, DLQI, and ADCT trends across phenotypes showed significant improvement in all phenotype subgroups. By week 16, classical and generalized lichenoid phenotypes showed the highest EASI improvements compared to the generalized inflammatory (75.0 vs. 45.5 [p < 0.001] and 79.3 vs. 45.5 [p < 0.001]), with most achieving EASI-75 (p < 0.001, χ2 = 25.96). By week 24, generalized lichenoid reached 100% EASI improvement, significantly outperforming other phenotypes. The highest EASI-75 rates were seen in classical, generalized lichenoid, and portrait/head and neck phenotypes (p = 0.016, χ2 = 13.85). No significant differences were observed at weeks 32, 40, or 52. Conclusions: Our results suggest that tralokinumab's durability and tolerability are consistent across the various phenotypes. The classical and generalized lichenoid were the fastest phenotypes to improve. However, given the uneven distribution of phenotypes and the gradual reduction in patient numbers over time, larger prospective studies are essential to confirm the observed trends.

Keywords: atopic dermatitis; tralokinumab.

PubMed Disclaimer

Conflict of interest statement

S. Ferrucci has conflicts of interest with Amgen, Sanofi, Novartis, Lilly, LEO Pharma, Abbvie, Menarini. F. Barei has conflicts of interest with LEO Pharma and Almirall. M.B. Guanti has conflicts of interest with LEO Pharma, Abbvie, Sanofi, Menarini, Novartis, Cantabria, Lilly, Pfizer, and Firma. I. Trave has conflicts of interest with Abbvie, LEO Pharma, Galderma, and Novartis. E. Cozzani has conflicts of interest with Eli Lilly. M. Rossi has conflicts of interest with Abbvie, Sanofi, LEO Pharma, Pfizer, L’Oréal, and Almirall. E. Nettis has conflicts of interest with Sanofi, Abbvie, LEO Pharma, GSK, and AstraZeneca. K. Hansel has conflicts of interest with AbbVie, Almirall, Eli Lilly, LEO Pharma, Sanofi, and UCB. L. Stingeni has conflicts of interest with AbbVie, Almirall, Amgen, Bristol Meyer Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, and Sanofi. E. Pezzolo has conflicts of interest with Sanofi, LEO Pharma, Abbvie, and Pfizer. Novartis, Galderma, Janssen, Almirall, and Boehringer Ingelheim. F. Caroppo has conflicts of interest with Sanofi, LEO Pharma, Amgen, Novartis, and Abbvie. A. Belloni Fortina has conflicts of interest with Sanofi, LEO Pharma, Amgen, Novartis, Abbvie, Eli Lilly, Unifarco, and Almirall. G. Girolomoni has conflicts of interest with AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, LEO Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis, and Sanofi. S. Ribero has conflicts of interest with Sanofi, Abbvie, Almirall, UCB Pharma, Novartis, LEO Pharma, and Eli Lilly. Angelo Valerio Marzano has conflicts of interest with AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, and UCB. Anna Campanati has conflicts of interest with AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi and Janssen, and UCB. The other authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Distribution of phenotypes in the study population. Abbreviations: Gen., generalized; PN, prurigo nodularis; NE, nummular eczema.
Figure 2
Figure 2
Endpoint of EASI-75, EASI-90, and EASI-100 at week 52 among the different phenotypes. Abbreviations: Gen., generalized; PN, prurigo nodularis; NE, nummular eczema.
See this image and copyright information in PMC

References

    1. Weidinger S., Beck L.A., Bieber T., Kabashima K., Irvine A.D. Atopic dermatitis. Nat. Rev. Dis. Primers. 2018;4:1. doi: 10.1038/s41572-018-0001-z. - DOI - PubMed
    1. Böhner A., Jargosch M., Müller N.S., Garzorz-Stark N., Pilz C., Lauffer F., Wang R., Roenneberg S., Zink A., Thomas J., et al. The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response. J. Allergy Clin. Immunol. 2023;152:408–419. doi: 10.1016/j.jaci.2023.04.009. - DOI - PubMed
    1. Bieber T., D’Erme A.M., Akdis C.A., Traidl-Hoffmann C., Lauener R., Schäppi G., Schmid-Grendelmeier P. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J. Allergy Clin. Immunol. 2017;139:58–64. doi: 10.1016/j.jaci.2017.01.008. - DOI - PubMed
    1. Mesjasz A., Kołkowski K., Wollenberg A., Trzeciak M. How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? Int. J. Mol. Sci. 2023;20:7557. doi: 10.3390/ijms24087557. - DOI - PMC - PubMed
    1. Wollenberg A., Blauvelt A., Guttman-Yassky E., Worm M., Lynde C., Lacour J.P., Spelman L., Katoh N., Saeki H., Poulin Y., et al. ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) Br. J. Dermatol. 2021;184:437–449. doi: 10.1111/bjd.19574. - DOI - PMC - PubMed